Skip to main content
康乐卫士 logo

康乐卫士 — Investor Relations & Filings

Ticker · 920575 ISIN · CNE1000059W8 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 537 across all filing types
Latest filing 2025-06-04 Share Issue/Capital Cha…
Country CN China
Listing Beijing Stock Exchange 920575

About 康乐卫士

https://www.klws.com/

Beijing Health Guard Biotechnology Inc. is a clinical-stage biopharmaceutical company specializing in the research, development, and commercialization of innovative recombinant human vaccines. The company leverages advanced structural biology and protein engineering platforms to create a diverse pipeline of vaccine candidates. Its primary focus includes the development of high-valent human papillomavirus (HPV) vaccines, with its trivalent and nine-valent candidates in late-stage clinical trials. Additionally, the company is advancing candidates for respiratory syncytial virus (RSV), shingles, and other infectious diseases. By utilizing recombinant protein technology, Health Guard aims to provide high-quality, affordable immunization solutions to address significant unmet medical needs. Its technical expertise encompasses antigen design, high-throughput screening, and large-scale manufacturing processes.

Recent filings

Filing Released Lang Actions
股票解除限售公告
Share Issue/Capital Change Classification · 95% confidence The document is a stock-related announcement from Beijing Kangle Weishi Biotechnology Co., Ltd. It details the lifting of trading restrictions on a specific number of shares, including shareholder details, reasons for lifting restrictions, and post-lifting share capital structure. The document is short (1489 characters) and focuses on share trading status changes rather than financial results or management changes. It does not contain financial statements or earnings data, nor is it a report or presentation. The content fits the category of announcements related to share capital changes, specifically the lifting of share restrictions, which is a capital change event. Therefore, the appropriate classification is Share Issue/Capital Change (SHA).
2025-06-04 Chinese
北京观韬律师事务所关于北京康乐卫士生物技术股份有限公司2024年年度股东会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the convening, procedures, and results of the 2024 Annual General Meeting (AGM) of Beijing Kang Le Wei Shi Biotechnology Co., Ltd. It details the legality and validity of the AGM's call, attendance, voting procedures, and resolutions passed. The document does not contain financial statements or detailed financial performance data but focuses on the legal aspects of the AGM process and voting results. This matches the description of 'Declaration of Voting Results & Voting Rights Announcements (DVA)', which covers official results from shareholder votes at any general meeting. The document length is about 5,766 characters, which is sufficient for a detailed voting results announcement but not a full annual report or audit report. Therefore, the correct classification is DVA with high confidence.
2025-05-20 Chinese
2024年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a "2024 Annual General Meeting Resolution Announcement" for Beijing Kangle Weishi Biotechnology Co., Ltd. It details the convening and attendance of the 2025 AGM, lists the resolutions passed including approval of the 2024 annual reports, financial statements, audit reports, budget reports, and other governance matters. It includes voting results and legal opinions confirming the validity of the meeting and resolutions. The document is a formal announcement of the shareholder meeting decisions and voting outcomes rather than the full annual report or audit report itself. The length is about 4,054 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits best under the category of "Declaration of Voting Results & Voting Rights Announcements (DVA)" as it officially announces the voting results of the AGM.
2025-05-20 Chinese
中信证券股份有限公司关于北京康乐卫士生物技术股份有限公司2024年年度持续督导跟踪报告
Regulatory Filings Classification · 95% confidence The document is titled as a "2024 Annual Continuous Supervision Tracking Report" by CITIC Securities for Beijing Kangle Weishi Biotechnology Co., Ltd. It details the continuous supervision work performed by the sponsor institution, including information disclosure review, compliance with securities laws, and monitoring of fundraising usage. The content focuses on regulatory compliance, supervision activities, and reporting to the stock exchange and securities commission. It does not contain financial statements or detailed financial performance data typical of an Annual Report (10-K) or Interim Report (IR). It is a formal report on ongoing regulatory supervision and compliance rather than a financial or earnings report. This type of document aligns with the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories. The document length (4811 characters) and detailed supervisory content support this classification rather than a brief announcement or a full financial report.
2025-05-20 Chinese
投资者关系活动记录表
Call Transcript Classification · 95% confidence The document is titled as an "投资者关系活动记录表" which translates to "Investor Relations Activity Record". It details an "业绩说明会" (performance explanation meeting) held on May 15, 2025, discussing the 2024 annual report results. The content includes Q&A about clinical progress, financing, and company strategy, typical of an earnings or performance explanation session. The document is about 4,521 characters, which is relatively short and focuses on a meeting discussing the annual report results rather than the full annual report itself. It is not a full financial report but a transcript or summary of an earnings presentation or performance explanation meeting. Therefore, it fits best as a Call Transcript (CT) or Earnings Release (ER). However, since it is a detailed Q&A session from an earnings explanation meeting, it aligns more closely with a Call Transcript (CT) rather than a brief Earnings Release (ER). Hence, the classification is CT with high confidence.
2025-05-15 Chinese
2024年年度报告业绩说明会预告公告
AGM Information Classification · 95% confidence The document is a notice about an upcoming performance explanation meeting related to the company's 2024 Annual Report. It mentions the date and time of the meeting, the participants, and how investors can join online. The document does not contain the actual annual report or detailed financial data but rather announces the event to discuss the annual report. The document length is short (1159 characters), and it serves as an announcement rather than the report itself. According to the 'Menu vs Meal' rule, this is a report publication announcement or related event notice, not the annual report itself. Therefore, the appropriate classification is AGM Information (AGM-R) since it is about an annual report performance explanation meeting, which is a type of AGM-related presentation or material.
2025-05-12 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.